PL1797871T3 - Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania - Google Patents
Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzaniaInfo
- Publication number
- PL1797871T3 PL1797871T3 PL05792179T PL05792179T PL1797871T3 PL 1797871 T3 PL1797871 T3 PL 1797871T3 PL 05792179 T PL05792179 T PL 05792179T PL 05792179 T PL05792179 T PL 05792179T PL 1797871 T3 PL1797871 T3 PL 1797871T3
- Authority
- PL
- Poland
- Prior art keywords
- preparation
- receptor agonist
- release formulation
- formulation containing
- dopamine receptor
- Prior art date
Links
- 229940098778 Dopamine receptor agonist Drugs 0.000 title 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200410077961 | 2004-09-21 | ||
| PCT/CN2005/001521 WO2006032202A1 (fr) | 2004-09-21 | 2005-09-21 | Formulation à libération lente et prolongée contenant un agoniste du récepteur de la dopamine et son procédé de préparation |
| EP05792179.3A EP1797871B1 (en) | 2004-09-21 | 2005-09-21 | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1797871T3 true PL1797871T3 (pl) | 2015-07-31 |
Family
ID=36089849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL05792179T PL1797871T3 (pl) | 2004-09-21 | 2005-09-21 | Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US8691277B2 (enExample) |
| EP (1) | EP1797871B1 (enExample) |
| JP (1) | JP5081622B2 (enExample) |
| KR (1) | KR20070059161A (enExample) |
| AU (1) | AU2005287743B2 (enExample) |
| CA (1) | CA2581143C (enExample) |
| ES (1) | ES2536460T3 (enExample) |
| PL (1) | PL1797871T3 (enExample) |
| WO (1) | WO2006032202A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
| US8475829B2 (en) * | 2006-04-06 | 2013-07-02 | Nupathe Inc. | Implants for the treatment of dopamine associated states |
| US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
| CA2654719A1 (en) * | 2006-06-16 | 2007-12-21 | Solvay Pharmaceuticals B.V. | Combination preparations comprising slv308 and a l-dopa |
| US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
| TWI392670B (zh) | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途 |
| WO2008009665A1 (en) * | 2006-07-19 | 2008-01-24 | Boehringer Ingelheim International Gmbh | Treatment of pain |
| US20090304794A1 (en) * | 2008-06-09 | 2009-12-10 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of pramipexole |
| EP2452677A1 (en) | 2008-09-29 | 2012-05-16 | Wockhardt Limited | Extended release dosage form of ropinirole |
| FR2936710B1 (fr) * | 2008-10-07 | 2011-01-07 | Ceva Sante Animale | Composition veterinaire antiprolactinique destinee aux ruminants |
| AU2010266285A1 (en) * | 2009-07-02 | 2012-02-09 | Supernus Pharmaceuticals, Inc. | A method of treatment of a neurological disorder |
| WO2011012721A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Carrier linked pramipexole prodrugs |
| WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
| DE102010014113A1 (de) * | 2010-04-07 | 2011-10-13 | Acino Ag | Freisetzungsverfahren für Implantate |
| AU2011334494B2 (en) * | 2010-11-25 | 2015-11-05 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative |
| EA201300607A8 (ru) * | 2010-12-02 | 2014-02-28 | Ратиофарм Гмбх | Ионная жидкость ротиготина |
| US9956201B2 (en) | 2014-07-21 | 2018-05-01 | Spriaso Llc | Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms |
| WO2018096560A1 (en) | 2016-11-23 | 2018-05-31 | Cipla Limited | Long acting depot formulation for the continuous dopaminergic stimulation |
| WO2019234069A1 (en) | 2018-06-08 | 2019-12-12 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising pergolide |
| KR102212722B1 (ko) * | 2019-12-23 | 2021-02-08 | 환인제약 주식회사 | 로피니롤을 포함하는 마이크로스피어 및 이를 함유하는 주사제 조성물 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166800A (en) * | 1977-08-25 | 1979-09-04 | Sandoz, Inc. | Processes for preparation of microspheres |
| JP2651320B2 (ja) | 1992-07-16 | 1997-09-10 | 田辺製薬株式会社 | 徐放性マイクロスフェア製剤の製造方法 |
| DE69734060T2 (de) * | 1996-05-24 | 2006-06-29 | Angiotech Pharmaceuticals, Inc., Vancouver | Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege |
| EP0930874A2 (en) | 1996-10-09 | 1999-07-28 | Takeda Chemical Industries, Ltd. | A method for producing a microparticle |
| JPH10167968A (ja) * | 1996-10-09 | 1998-06-23 | Takeda Chem Ind Ltd | マイクロパーティクルの製造法 |
| PT949905E (pt) * | 1996-12-20 | 2001-12-28 | Alza Corp | Composicao de gel injectavel de efeito retardado e processo para a sua preparacao |
| JP3663271B2 (ja) * | 1997-01-24 | 2005-06-22 | シュバルツ ファルマ アクチェンゲゼルシャフト | 新規の分枝鎖エステル及びその製法 |
| ATE428371T1 (de) * | 1998-07-17 | 2009-05-15 | Pacira Pharmaceuticals Inc | Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen |
| US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
| MEP19408A (en) * | 1998-12-16 | 2010-06-10 | Aventis Pharma Inc | Biodegradable polymer encapsulated serotonin receptor antagonist and method for preparing the same |
| GB9828861D0 (en) * | 1998-12-31 | 1999-02-17 | Danbiosyst Uk | Compositions |
| JP4540280B2 (ja) | 1999-07-09 | 2010-09-08 | ベーテーエス ホールディング インターナショナル ベー ヴィ | 光学走査装置 |
| JP4287613B2 (ja) | 2000-04-28 | 2009-07-01 | 田辺三菱製薬株式会社 | マイクロスフェアの製法 |
| DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
| DE10055742B4 (de) * | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| KR20040005936A (ko) * | 2001-04-26 | 2004-01-16 | 컨트롤 딜리버리 시스템즈 인코포레이티드 | 공동약물을 함유하는 서방 약물 전달 시스템 |
| EP1572154B1 (en) * | 2002-11-18 | 2012-02-01 | Rutgers, The State University of New Jersey | Medical devices employing novel polymers |
| EP1610791B1 (en) * | 2003-03-31 | 2011-02-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of dopamine agonist |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
-
2005
- 2005-09-21 EP EP05792179.3A patent/EP1797871B1/en not_active Expired - Lifetime
- 2005-09-21 KR KR1020077008896A patent/KR20070059161A/ko not_active Ceased
- 2005-09-21 AU AU2005287743A patent/AU2005287743B2/en not_active Ceased
- 2005-09-21 ES ES05792179.3T patent/ES2536460T3/es not_active Expired - Lifetime
- 2005-09-21 JP JP2007532749A patent/JP5081622B2/ja not_active Expired - Lifetime
- 2005-09-21 CA CA2581143A patent/CA2581143C/en not_active Expired - Fee Related
- 2005-09-21 WO PCT/CN2005/001521 patent/WO2006032202A1/zh not_active Ceased
- 2005-09-21 PL PL05792179T patent/PL1797871T3/pl unknown
- 2005-09-21 US US11/663,411 patent/US8691277B2/en active Active
-
2014
- 2014-03-17 US US14/182,652 patent/US9220782B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1797871A4 (en) | 2012-11-28 |
| WO2006032202A1 (fr) | 2006-03-30 |
| CA2581143C (en) | 2015-03-31 |
| US20080260846A1 (en) | 2008-10-23 |
| US8691277B2 (en) | 2014-04-08 |
| ES2536460T3 (es) | 2015-05-25 |
| US9220782B2 (en) | 2015-12-29 |
| JP2008513524A (ja) | 2008-05-01 |
| CA2581143A1 (en) | 2006-03-30 |
| JP5081622B2 (ja) | 2012-11-28 |
| EP1797871A1 (en) | 2007-06-20 |
| KR20070059161A (ko) | 2007-06-11 |
| HK1107012A1 (en) | 2008-03-28 |
| AU2005287743B2 (en) | 2011-09-29 |
| EP1797871B1 (en) | 2015-02-25 |
| AU2005287743A1 (en) | 2006-03-30 |
| US20140255488A1 (en) | 2014-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1797871T3 (pl) | Długo działający preparat o przedłużonym uwalnianiu zawierający agonistę receptora dopaminowego i sposób jego wytwarzania | |
| IL184167A0 (en) | Compositions comprising anti-igf-1 receptor antibodies and methods for obtaining said antibodies | |
| IL183384A0 (en) | Composition comprising a sustained release coating or matrix and an nmda receptor antagonist, method for administration such nmda antagonist to a subject | |
| IL183541A0 (en) | Toll like receptor 3 antagonists, methods and uses | |
| HUP0401191A3 (en) | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation | |
| GB0616752D0 (en) | Formulation evaluation system and method | |
| AU2003238597A8 (en) | Benzimidazole compounds and their use as estrogen agonists/antagonists | |
| ZA200803668B (en) | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | |
| IL209402A (en) | A process for making opioid receptor regulators and opioid receptor regulators made by him | |
| IL169575A0 (en) | Calcium-sensing receptor antagonist compounds and pharmaceutical compositions containing the same | |
| EP1814550A4 (en) | ANTAGONISTS OF N-SULFONYLPIPERIDINE CANNABINOID RECEPTOR 1 | |
| TWI341198B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| IL177665A0 (en) | Novel pharmaceutical compositions comprising agonists of the thyroid receptor | |
| AU2003251705A1 (en) | Idol derivatives as new thyroid receptor agonist ligands and methods | |
| EP1937223A4 (en) | PELLET FORMULATION OF AN ALPHA1 RECEPTOR ANTAGONIST WITH DELAYED RELEASE AND METHOD OF MANUFACTURING THEREOF | |
| AP2006003840A0 (en) | Indole-2-carboxamidine derivatives as NMDA receptor antagonists | |
| IL176485A0 (en) | Agonist anti-trkc antibodies and methods using same | |
| AU2003280675A1 (en) | SELECTIVE HUMAN Beta3 ADRENALIN RECEPTOR AGONIST AGENT | |
| AU2003243246A1 (en) | In situ methods for measuring the release of a substance from a dosage form | |
| HUP0200057A3 (en) | Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use | |
| ZA200705206B (en) | Toll like receptor 3 antagonists, methods and uses | |
| ZA200704791B (en) | Tablets for the sustained release of indapamide and preparation method thereof | |
| ZA200605574B (en) | Hydroisoindoline tachykinin receptor antagonists | |
| GB0408398D0 (en) | Leptin receptor agonists (3) | |
| GB0408454D0 (en) | Leptin receptor agonists (1) |